Could licorice root make CAR-T cancer therapy safer and stronger?

NCT ID NCT07616271

Not yet recruiting Disease control Sponsor: Tongji Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a compound from licorice root, called diammonium glycyrrhizinate, can reduce the toxic side effects and improve the cancer-killing power of CAR-T cell therapy in people with large B-cell lymphoma. About 21 participants will receive either standard care or the licorice extract alongside their CAR-T treatment, and researchers will track side effects and remission rates. The goal is to make this advanced therapy both safer and more effective.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: diammonium glycyrrhizinate (a compound from licorice root)
What this could lead to: If it works, this could make CAR-T cell therapy safer and more effective for people with large B-cell lymphoma.
What could go wrong: This is a small, early-stage trial with only 21 participants, so results may not apply to everyone. The treatment requires taking the drug for 2 years, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PATIENTS WITH LARGE B-CELL LYMPHOMA RECEIVING CAR-T CELL THERAPY

More trials for these conditions

Other studies related to the condition(s) this trial covers.